Objectives/Hypothesis: Head and neck squamous cell carcinoma (HNSCC) cells are resistant to cell death induced by tumor necrosis factor ligands such as tumor necrosis factor a (TNFa) or TNF-related apoptosis-inducing ligand (TRAIL) and cytotoxic chemotherapies. Recently, genetic alterations in cell death pathways, including inhibitor of apoptosis proteins, have been demonstrated in HNSCC. We investigated the effects of birinapant, a novel, second mitochondria-derived activator of caspases (SMAC)-mimetic that targets inhibitor of apoptosis proteins, alone and in combination with TNFa, TRAIL, or chemotherapy docetaxel.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, with over 600,000 new cases diagnosed each year. 1 Despite advances in treatment options including surgery, chemotherapy, and radiation therapy, the 5-year survival remains approximately 50%. 1 With the development of novel targeted molecular therapies and the large-scale efforts to characterize and catalog genomic changes in tumors by projects such as The Cancer Genome Atlas (TCGA), there is renewed hope for improvement of HNSCC treatment and outcomes.
Resistance of tumor cells to cell death signals, chemotherapy, or radiation therapy-induced cell death is a significant problem promoting the development and progression of HNSCC. Cell death may be induced by ligands and receptors of the tumor necrosis factor/Fas receptor family. 2 These receptors induce cytoplasmic complexes and a signal cascade involving Fas-associated death domain (FADD) protein, which can promote caspase 8-(CASP8) and 3-mediated apoptosis. 2, 3 However, this signaling and cell death may be blocked by Inhibitors of apoptosis proteins (IAPs), which are encoded by baculoviral IAP repeat containing (BIRC) family genes 2 (Supp. Fig. S1 ).
Interestingly, recent findings from TCGA and other studies reveal that more than 40% of HNSCC harbor genomic alterations in these cell death pathways, with 30% displaying amplifications of FADD with or without coamplification of IAP genes BIRC2/3, whereas 10% form a mutually exclusive subset exhibiting mutations in CASP8. 4 Expression of IAPs BIRC2 and 3 are associated with chemoresistance and poor outcomes in a variety of cancer types. 5 In head and neck squamous cell carcinomas, cIAP1/BIRC2 expression was also correlated with nodal metastasis and with advanced disease. 6, 7 Moreover, binding of tumor necrosis factor a (TNFa) to its receptor in the presence of cIAP1/BIRC2 and cIAP2/ BIRC3 leads to activation of nuclear factor-kappaB (NF-OEB) transcription factors, which can promote expression of genes that further enhance cell survival, therapeutic drug resistance, and malignant progression. 8 However, when BIRC2/3 are inhibited, TNFa or cytotoxic damage signaling instead leads to FADD-mediated cell death. 8, 9 Birinapant is a potent inhibitor of cIAPs that structurally mimics the second mitochondria-derived activator of caspases (SMAC). SMAC is an endogenous protein released by mitochondria at the onset of apoptosis, which controls IAPs by binding to them and leading to their degradation, thereby enhancing apoptosis. 8 A growing area of interest in cancer research involves targeting IAPs with small molecule mimetics of SMAC as a method of inducing cell death in cancer cells. Birinapant has demonstrated activity in preclinical models of melanoma, colorectal, ovarian, 10 and breast cancer, 11 and is currently in phase I/II clinical trials in these tumor types. 12 Because HNSCC exhibit genomic alterations and increased expression of FADD and IAPs/BIRCs, we explored the hypothesis that birinapant may induce cell death alone, or in combination with TNFa, TRAIL, or docetaxel (a chemotherapy approved and commonly used in patients with HNSCC). Strategies that identify new targets for cytotoxic therapy and address resistance to standard chemotherapy agents such as docetaxel are important areas of pursuit for improvement of treatment in patients with HNSCC.
MATERIALS AND METHODS

Cell Lines and Cell Culture
HNSCC cell lines University of Michigan squamous cancer cell carcinoma (UMSCC)1, 11B, and 46 were obtained from Dr. T. E. Carey at the University of Michigan (Ann Arbor, MI). 13, 14 These lines have been characterized for genomic alterations and expression of FADD, BIRC2/3, and CASP8 (Supp. Fig. S2 ). Cell lines were maintained in Minimal Essential Medium (MEM) (Gibco, Grand Island, NY), supplemented with 10% fetal calf serum (Gibco), 1% penicillin/streptomycin (Gibco), 1% Lglutamine (Gibco), and used for experiments within 3 months or 20 passages. Cultures were incubated at 37 C with 5% CO 2 .
XTT Cell Proliferation Assays
To determine single agent and combination drug effects in vitro, XTT Cell Proliferation Kits (Roche, Indianapolis, IN) were used. Cells were plated in 96-well plates at predetermined densities for each cell line based on respective doubling times and log-phase growth patterns. Cells were treated with 0.01% dimethyl sulfoxide (DMSO) control or one of nine concentrations of birinapant 6 20 ng/mL TNFa or 50ng/ml TRAIL (R&D systems, Minneapolis, MN) 6 docetaxel (LC Laboratories, Woburn, MA), and cell density measured by XTT Cell Proliferation Kits (Roche) on a microplate reader on days 1, 3, and 5. Each cell line and dilution was assayed in six replicates. Inhibitory concentration 50% (IC 50 ) was determined on day 3 using the nonlinear four-parameter regression function in GraphPad Prism (La Jolla, CA). For drug combination studies, fixed ratios of each drug's respective IC 50 in each cell line was used to determine additivity, synergism, or antagonism.
Flow Cytometric Analysis of Cell Cycle and Death
Flow cytometry was used to elucidate the effect of drug on cell cycle and cell death in UMSCC-46 and 211B using Cycletest Plus DNA Reagent Kit (BD BioSciences, San Jose, CA). Cells were plated 48 hours before treatment, and treated over 24 hours with 0.01% DMSO control, 20 ng/mL TNFa, 1 mM birinapant, or combinations of each. Cells were harvested, counted, and stained with propidium iodide prior to analysis on a FACS Canto flow cytometer (BD Biosciences). Data from 10,000 cells per treatment group and time point were analyzed using BD FACSDiva (BD Biosciences) software. Each experiment was performed in triplicate.
HNSCC Xenograft Studies
All animal experiments were carried out under protocol #1322, approved by the Animal Care and Use Committee of the National Institute on Deafness and Other Communication Disorders, and were in compliance with the Guide for the Care and Use of Laboratory Animal Resource (1996) National Research Council. Four-to 6-week-old female severe combined immunodeficiency/NCr-Balb/c mice were obtained from Frederick Cancer Research and Development Center (National Cancer Institute) and housed in a specific pathogen-free animal facility. Mice were inoculated with 5 3 10 6 UMSCC-46 cells injected subcutaneously in 0.2-mL blank MEM media into the right hind flanks. Fourteen days later, once tumors became palpable, mice were randomized into treatment arms (vehicle control n 5 20, 15 mg/kg Birinapant n 5 20, 6 mg/kg docetaxel n 5 20, combination n 5 20). Birinapant was formulated at 1.5 mg/mL in a citrate buffer solution on each treatment day, and administered by intraperitoneal injections (i.p.) for the 3-week treatment period on Wednesdays and Thursdays, whereas docetaxel was administered i.p. on Wednesdays, based on previously published studies. 10, 15 Control mice received citrate buffer solution as a vehicle on the same schedule. Tumor diameters were measured in two dimensions using electronic calipers, and volume was estimated using the formula V 5 0.5 (L 3 W 3 W), where L equals the longer of the two measurements. Mice were euthanized when tumors reached 2 cm in diameter, were ulcerated and bleeding, or if mice suffered from pain or weight loss.
Statistical Design for Data Analysis
Data from XTT assays and flow cytometric experiments were presented as mean 6 standard deviation of at least three replicates. For in vitro drug combination studies, interactions were analyzed by the Chou-Talalay method using CompuSyn software (Combosyn, Inc, Paramus, NJ) (Combination Index (CI) < 1: synergy, CI 5 1: additivity, CI > 1: antagonism). 16 For XTT assays, t tests were performed at each concentration tested for TNF versus birinapant alone and TRAIL versus birinapant alone. Curves were considered significantly different if the majority of points assessed were statistically significant, with P values of less than 0.05. For flow cytometric experiments and tumor growth analysis, significance was determined using the t test, with P values of less than 0.05 considered statistically significant. For survival analysis, the Gehan-Breslow-Wilcoxon test was used, and significance set to 0.05 using the Bonferroni method.
RESULTS
Birinapant Differentially Affects HNSCC Proliferation In Vitro and Is Enhanced by TNF and TRAIL
We selected three human HNSCC cell lines with varying alterations in cell death pathway components for examination of sensitivity to birinapant or docetaxel. Compared with normal keratinocytes, UMSCC-1 is a cell line with similar low levels of FADD and BIRC2 expression, UMSCC-11B has both increased FADD and BIRC2 expression, whereas UMSCC-46 has increased FADD expression and normal BIRC2 (Supp. Fig. S2 ). All cell lines treated with increasing birinapant concentrations between 0.5 nmol/L and 10 mmol/L over a 5-day XTT assay exhibited a dose-dependent decrease in cell density (Fig. 1A) . The IC 50 values for birinapant for UMSCC-1 and 211B exceeded 1 mmol/L, whereas UMSCC-46 was sensitive to birinapant alone with an IC 50 11 nmol/L (Fig. 1A) . The addition of 20 ng/mL of TNFa or 50 ng/mL of TRAIL potently inhibited cell density and significantly enhanced the effects of birinapant in all three cell lines (P < 0.0001). Although UMSCC-1 and 211B were both relatively resistant to single-agent birinapant, with < 50% inhibition even at maximal concentrations of 1 mM, sensitization with TNFa or TRAILreduced IC 50 values to 45 and 18 nmol/L for birinapant for UMSCC-1, and to 42 and 40 nmol/L for UMSCC-11B, respectively (Fig. 1A) . For UMSCC-46, costimulation with either TNFa or TRAIL further reduced the IC 50 from 11 nmol/L to 0.72 and 0.57 nmol/L, respectively (Fig. 1A) . We then established sensitivity of our cell lines to conventional chemotherapy docetaxel prior to use in combinations. When treated with increasing concentrations, all three cell lines demonstrated sensitivity to docetaxel in vitro, with IC 50 values under 3 nmol/L (Fig. 1B) .
Birinapant 6 TNF Alters Cell Cycle Distribution and Increases Cell Death
To further evaluate the effects of birinapant on cell cycle or death in UMSCC-46 and 211B, DNA cytofluorometric analyses were performed (Fig. 2) . In UMSCC-46, cells treated with birinapant or birinapant and TNF exhibited significantly increased sub-G 0 DNA fragmentation at 24 hours, indicating a marked effect on cell death (Figs. 2A,C) . The combined effect of TNF and birinapant was significantly more effective at inducing cell death than birinapant alone (P < 0.05). Additionally, a significant increase in G2/M phase population was observed with birinapant alone and enhanced with the addition of TNF (P < 0.01). In UMSCC-11B, the combination of TNF with birinapant also significantly increased cell death (P < 0.01), whereas birinapant alone did not have an effect (Figs. 2C,D) . In this cell line, there were no other changes in cell cycle distribution in response to treatment. The greater effects on subG0 DNA and G2/M are consistent with the relatively higher sensitivity of UMSCC-46 observed with birinapant alone or in combination with TNF. Fig. 2 . Effects of birinapant and TNF on cell cycle and cell death. UMSCC-46 or 211B cells were plated in monolayer for 48 hours, and treated with birinapant and TNF alone or in combination. Cells were harvested for cell cycle analysis at 24 hours posttreatment and analyzed by DNA cytofluorometry. Representative histograms (A, B) and summary data of three independent experiments shown (C, D). Summary data were calculated and presented as mean 6 standard deviation, and statistical significance was calculated by t test as indicated.
Birinapant Demonstrates Synergistic Activity With Docetaxel in HNSCC Cell Lines In Vitro
To determine the effect of birinapant in combination with the conventional chemotherapy docetaxel widely used in HNSCC, XTT assays were performed in birinapant-resistant UMSCC-1 or sensitive UM-SCC-46 cells for combinations of birinapant with docetaxel with or without TNFa. Combinations were performed at fixed ratios spanning previously estimated IC 50 values for each drug, using 0.25 to 8 times the IC 50 . Figure 3A confirms that compared to UMSCC-1, UMSCC-46 was relatively more sensitive to lower concentrations of birinapant alone. However, both lines showed evidence of significantly increased response to combination treatment compared to either drug alone at higher concentrations (P < 0.05). The combination index of each experiment was determined by the Chou-Talalay method using CompuSyn software, which defines synergism as a combination index < 0.9 and antagonism > 1.1 (Fig. 3B) . For UMSCC-46, birinapant and docetaxel were synergistic between 0.5-4 nM, and a similar result was seen without or with the addition of TNFa. In UMSCC-1, evidence for synergism at lower concentrations was observed only with the addition of TNFa (Fig. 3B) . These results suggested that birinapant alone or in combination with docetaxel may be more active in HNSCC cell lines such as UMSCC-46 that are sensitive to birinapant alone.
Combination Effects of Birinapant and Docetaxel in a UMSCC-46 Xenograft Model
Based on the above studies providing evidence for sensitivity of UMSCC-46 to birinapant alone and in combination with docetaxel, we evaluated the activity of these treatments in HNSCC in vivo. Nine days into the treatment period, birinapant alone demonstrated a significant difference in tumor volume compared to control (P < 0.05) (Fig. 4A) . Surprisingly, docetaxel showed no single agent activity in vivo, despite sensitivity of the cell line in vitro. The combination treated group exhibited significantly decreased tumor volumes compared to control (P < 0.05), with prolonged activity compared to the birinapant monotherapy group. Birinapant as a single agent significantly improved survival to a median of 60 days compared to 38 days in control animals (P < 0.01) (Fig. 4B) . Docetaxel alone and the combination treatment did not reach significance in the survival analysis.
DISCUSSION
In this study, we demonstrate that human HNSCC cell lines with varying alterations in cell death pathway molecules exhibit differential sensitivity to birinapant alone or when costimulated with either TNFa or TRAIL in vitro. Interestingly, UMSCC-46, a mutant TP53 cell line with FADD overexpression but cIAP1 expression similar to keratinocytes, was highly sensitive to birinapant monotherapy. Meanwhile, UMSCC-1 and 211B lines exhibiting relatively low or high levels of both FADD and BIRC2, respectively, were relatively resistant to birinapant alone, but sensitized by combination with TNFa or TRAIL. We also found that the combination of TNF and birinapant induced increased cell death and cell cycle changes compared to either treatment alone in UMSCC-46 and 211B. One possible explanation for the differential sensitivity of the cell lines to birinapant is that the balance between cell death protein FADD and its antagonist cIAP1 (BIRC2) may affect intrinsic baseline sensitivity to IAP inhibitors such as birinapant. However, both of the other lines exhibited sensitization to the combination of TNFa/TRAIL with birinapant, consistent with previously established effects of birinapant in degrading cIAP1. In future studies it will be interesting to examine if high levels of FADD are predictive of response when inhibiting cIAP1 using a SMAC mimetic, or modified by the presence of relatively higher levels of cIAP1, as in UMSCC-11B.
Based on publically available TCGA data, 30% of human HNSCC exhibit amplification of FADD and 8% coamplification with BIRC2/3 (cIAP1/2), rendering HNSCC among cancers with the highest prevalence of these death pathway alterations potentially actionable for investigation of SMAC mimetics. Because many patients exhibit intrinsic or acquired resistance to standard chemotherapy agents, which may be in part due to evasion of apoptosis, we also explored the potential of birinapant to overcome this resistance and sensitize HNSCC to the conventional chemotherapy drug docetaxel. In cell density assays, we demonstrated potential synergistic activity between birinapant and docetaxel at a range of doses without TNFa in UMSCC-46 and with TNFa in UMSCC-1.
Because of the sensitivity of UMSCC-46 cells to birinapant mono-and combined docetaxel therapy observed in vitro, we selected this cell line to further examine the effects of treatment in UMSCC-46 xenografts in vivo. Birinapant alone significantly inhibited tumor growth and prolonged survival > 20 days compared to control, consistent with activity observed in vitro. However, this cell line exhibited surprising resistance to docetaxel alone in vivo, despite being docetaxel-sensitive in vitro. Both birinapant and combination treated animals showed a similar significant delay in tumor growth during the treatment period, although there was a trend toward separation of their tumor growth curves afterward, with the combination group maintaining tumor growth delay for an additional week compared to birinapant alone. In the survival analysis, however, only birinapant monotherapy demonstrated a significantly improved overall survival compared to control animals.
There are a number of reasons why the synergistic response between birinapant and docetaxel that was observed in vitro may not have been clearly seen in vivo. The UMSCC-46 xenograft model was surprisingly resistant to docetaxel monotherapy in vivo, which may have masked a combination effect when given with birinapant. The separation between the birinapant and combination groups' tumor growth curves that emerged following the conclusion of the treatment period supports the idea that there is some differential effect of dual treatment. Because all treatments were given in a 48-hour span, an alternate schedule with a longer period of treatment could be explored for effects on enhancing the therapeutic window and activity. Alternatively, the limited activity could be due to other defects determining resistance to docetaxel. Although taxanes such as docetaxel may inhibit cell division and proliferation via their effects on microtubule assembly at similar concentrations in cell lines in short-term assays, cytotoxic effects of taxanes have been shown to be enhanced by wild type TP53, 17 whereas TP53 is mutated in UMSCC-46 18 and most HNSCC. 19 It would be of interest in future studies to determine if HNSCC with wtTP53 and greater sensitivity to cytotoxic effects of docetaxel alone would also demonstrate a greater combination effect when given with birinapant.
In conclusion, we have seen that TNF and TRAIL potently sensitize HNSCC lines to birinapant treatment. Several TRAIL compounds have been studied in clinical trials, and although they have been well tolerated, their anticancer responses have been poor. [20] [21] [22] Instead of using TRAIL or TNF itself, there is interest in finding ways to induce innate secretion of these cytokines. Recently, Beug et al. showed that certain viruses and adjuvants could stimulate a potent cytokine storm, inducing a release of TNF and TRAIL that lead to synergism with SMAC mimetics. 23 In head and neck cancer patients undergoing radiotherapy, there is evidence for induction of TNF. 24 Thus, patients undergoing radiotherapy may warrant investigational use of birinapant, particularly in those who have persistent or recurrent disease following definitive treatment.
CONCLUSION
SMAC mimetic birinapant as a monotherapy was able to significantly delay tumor growth and improve host survival in a human HNSCC xenograft model. Importantly, this effect was observed in a model that proved to be resistant to conventional chemotherapy with docetaxel in vivo, indicating potential for further investigation in patients with docetaxel chemotherapy resistant HNSCC. Provocatively, the UMSCC-46 model exhibits alterations similar to 30% of HNSCC with FADD amplifications by TCGA data. This subset exhibiting coamplification of FADD with oncogene cyclin D1 at the same locus is known to have an especially poor prognosis. Based on the results we observed in this project, this subset may be ideal candidates for investigational studies with a SMAC mimetic. Further studies with alternate dosing schedules, combinations, and additional animal models may help to establish optimal combinations of SMAC mimetic with chemotherapy or other cytotoxic therapies in HNSCC.
